Quantum Computing gets Wedbush backing for photonics opportunity despite profitability questions
Quantum Computing Inc. (QUBT) reported Q3 2026 revenue of $9.5M, beating estimates. Wedbush maintained a Neutral rating and $12 price target, citing solid revenue but unclear profitability path. Gross margin improved to 4.5%, and acquisitions drove growth. Wedbush adjusted revenue forecasts, raising 2027 and 2028 estimates but lowering 2027 gross margin expectations.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth, margin improvement, and cash balance, but profitability remains uncertain, leading to a neutral analyst stance.
Market read
QUBT's earnings beat offers limited trading opportunities; the neutral rating and modest loss suggest caution.
What to watch
Potential upside from the new Dirac‑3S shipment and first pharma customer could improve future margins if execution succeeds.
Background
Quantum Computing Inc. (QUBT) is a small‑cap photonics quantum‑computing company that recently completed several acquisitions and is expanding manufacturing capacity.
Ticker impact
QUBT reported Q3 revenue of $9.5M beating estimates and posted a loss of $0.07 per share, with Wedbush maintaining a neutral rating and $12 price target.
likely modest downside pressure as investors weigh profitability concerns against revenue beat
Revenue beat is positive, but widening loss and neutral rating limit bullish bias; small‑cap size limits magnitude.
Market effects
Highlights ongoing challenges for photonics‑focused quantum computing firms and may temper sector enthusiasm.
Limited to U.S. micro‑cap market; no broader regional effect.
Minimal global impact; primarily relevant to niche quantum‑computing investors.
Counterpoint
Despite the loss, the revenue beat and cash position could support a short‑term rally if the market underestimates the value of upcoming Fab expansion.
Key entities
- AnalystWedbush
Maintains neutral rating and $12 price target for QUBT.
- CustomerINmune Bio
First pharmaceutical/biotech customer for QUBT's Dirac‑3 system.
